Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Welichem Biotech has reported that Health Canada approved the company's clinical trial application to begin a Phase IIa trial of its anti-inflammatory drug candidate, WBI-1001, on atopic dermatitis.
Subscribe to our email newsletter
The company will initiate its Phase IIa trial of WBI-1001 as a topical cream application in the coming months. Atopic dermatitis is normally treated topically with corticosteroids or other immune-suppressors, and these treatments often result in adverse effects after long-term use. WBI-1001 has been developed as a more effective and tolerable topical treatment of this chronic disease.